Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Where Does Avastin Go From Here: Moving Beyond The C-08 Failure

Executive Summary

ORLANDO, Fla. - The full presentation of the C-08 trial of Roche/Genentech'sAvastin for use as adjuvant therapy in colorectal cancer - a landmark trial that failed to show an advantage for bevacizumab - at the American Society of Clinical Oncology annual meeting gave the sponsors some signs of encouragement

You may also be interested in...



C-08 Is Not The End Of Avastin’s Adjuvant Opportunity, Roche/Genentech Say

ORLANDO, Fla. - The failed C-08 trial does not signify the death knell of the adjuvant opportunity for Roche/Genentech's cancer drug Avastin, company executives assert

C-08 Is Not The End Of Avastin’s Adjuvant Opportunity, Roche/Genentech Say

ORLANDO, Fla. - The failed C-08 trial does not signify the death knell of the adjuvant opportunity for Roche/Genentech's cancer drug Avastin, company executives assert

Roche Checks Wallet As Important Avastin Trial Flops

Did Roche overpay for Genentech? Closely watched adjuvant trial for colon cancer fails to meet primary endpoint.

Topics

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel